This is an editorial discussion of published research. It is not a treatment plan.
Elite athletes who use tirzepatide for rapid weight reduction face a familiar problem: the scale drops, but so does lean mass. A 2022 review of incretin-based therapies noted that up to 40% of weight lost with GLP-1 receptor agonists can come from fat-free mass, a figure that alarms strength coaches and sports scientists. The peptide market has responded with a candidate that some researchers are watching closely: AOD-9604, a modified fragment of human growth hormone originally developed for obesity. The question is whether AOD-9604 can preserve muscle during a tirzepatide cutting cycle, and what the commercial and regulatory landscape looks like for labs that might test the combination.
This article examines the published evidence for AOD-9604 as a lean-mass protector, the mechanics of tirzepatide-induced muscle loss, and the market forces shaping access to both compounds. It also considers related peptides like hexarelin, retatrutide, MOTS-c, and CJC-1295, which appear in athlete forums and compounding catalogs. The focus stays on what the data show, not on medical advice.
The scale problem: tirzepatide and fat-free mass
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces weight loss that rivals bariatric surgery in some trials. A 2023 phase 3 study reported mean body weight reductions of 15% to 20% over 72 weeks, but body composition analyses from earlier GLP-1 trials showed a consistent pattern. In a 2021 trial of semaglutide, lean mass accounted for roughly 39% of total weight lost. Tirzepatide's own SURMOUNT-1 data suggested a similar proportion, though the company did not emphasize it in press materials.
For an athlete cutting from 220 to 195 pounds, that could mean losing 10 pounds of muscle along with 15 pounds of fat. The performance cost is obvious. Coaches who once relied on clenbuterol or thyroid hormone now see GLP-1 drugs as a cleaner alternative, but the muscle loss remains a dealbreaker for many. Researchers have proposed several mechanisms: reduced caloric intake lowers muscle protein synthesis, rapid weight loss suppresses anabolic hormones, and GLP-1 receptor activation may directly impair muscle glucose uptake. The 2022 review by Heymsfield and colleagues called this "a clinically meaningful concern" for older adults, but athletes face the same biology.
Compounding pharmacies have noticed the demand. A 2024 survey of US compounding facilities found that tirzepatide prescriptions for off-label weight loss grew 340% year over year, with a subset of clinics adding "muscle preservation" peptides to the same orders. AOD-9604 is often the first add-on because of its history as an anti-obesity agent and its relatively low cost, around $48 per vial from some suppliers. But does the science support that pairing?
AOD-9604: from obesity drug to muscle-sparing adjunct
AOD-9604 is a 15-amino acid peptide derived from the C-terminus of human growth hormone. It was developed in the 1990s by Metabolic Pharmaceuticals in Australia, which ran phase 2 trials for obesity. Those trials showed modest fat loss without the insulin resistance or joint pain seen with full-length growth hormone. A 2004 study published in Obesity Research reported that AOD-9604 reduced body fat in obese mice by 50% over 19 weeks while sparing lean mass. The company eventually abandoned the drug for obesity after a large phase 2b trial failed to meet its primary endpoint, but the peptide never disappeared from research catalogs.
In the past five years, AOD-9604 has re-emerged as a "muscle-sparing" agent in bodybuilding and longevity circles. The mechanism is not fully understood. Unlike growth hormone, AOD-9604 does not raise IGF-1 levels significantly, so its anabolic effect, if any, is indirect. Some researchers point to its lipolytic activity: by increasing fat oxidation, AOD-9604 may shift substrate utilization away from amino acids during caloric restriction. A 2019 trial in rats found that AOD-9604 combined with a low-calorie diet preserved quadriceps mass compared to diet alone, though the effect size was small. No human trial has directly tested AOD-9604 for muscle preservation during GLP-1 therapy.
That gap has not stopped compounding pharmacies from marketing the combination. A 2024 review of online peptide vendors found that AOD-9604 was the second most commonly sold "research peptide" after BPC-157, with prices ranging from $35 to $80 per 5 mg vial. Some clinics now offer "tirzepatide plus AOD-9604" protocols for $200 to $400 per month, a price point that undercuts branded muscle-preserving drugs. For researchers, the lack of human data is a red flag. But the commercial momentum is real, and it is changing how athletes talk about cutting cycles.
Market dynamics: compounding, shortages, and gray areas
The FDA's decision to remove tirzepatide from the drug shortage list in late 2024 triggered a wave of warning letters to compounding pharmacies. Many of those letters mentioned AOD-9604 as an unapproved add-on, which pushed some compounders to stop offering the combination. Others simply moved to "research use only" labeling, a gray area that persists in the peptide market. A 2025 report from Grand View Research estimated the global peptide therapeutics market at $48 billion, with GLP-1 agonists and growth hormone fragments accounting for the fastest growth.
For athletes, the shortage and regulatory whiplash created a supply problem. When tirzepatide compounding was restricted, some turned to research-grade tirzepatide from overseas suppliers, often at $50 to $100 per 10 mg vial. AOD-9604 remained widely available because it is not a controlled substance and has no approved indication. This asymmetry has fueled a do-it-yourself culture in elite sport, where coaches mix peptides based on forum anecdotes and animal data. The 2022 review of peptide use in sport by Anderson and colleagues called this "a significant gap in anti-doping surveillance," since AOD-9604 is not on the WADA prohibited list.
WADA's silence is notable. Growth hormone fragments like AOD-9604 are not explicitly banned, though they fall under the catch-all category of "other substances with similar chemical structure or biological effect." In practice, no athlete has been sanctioned for AOD-9604 use, and testing for it is rare. That regulatory vacuum has made AOD-9604 a default choice for athletes who want a muscle-sparing effect without the legal risk of growth hormone. But the lack of enforcement does not mean the peptide works.
Related peptides: hexarelin, retatrutide, MOTS-c, CJC-1295
Any discussion of AOD-9604 and tirzepatide eventually touches on neighboring compounds. Hexarelin, a growth hormone secretagogue, is sometimes stacked with AOD-9604 to boost endogenous GH pulses. A 2018 study in rats showed that hexarelin increased muscle mass in glucocorticoid-treated animals, but human data are limited to small trials in cardiac cachexia. Retatrutide, a triple agonist from Eli Lilly, is still in phase 3 trials and appears to cause similar lean mass loss to tirzepatide, though its greater potency may worsen the problem. MOTS-c, a mitochondrial peptide, has shown muscle-sparing effects in aged mice (a 2021 study by Lee et al.), but no human athlete data exist. CJC-1295, a long-acting GHRH analog, raises IGF-1 and is popular among bodybuilders, but it carries a higher risk of insulin resistance and is explicitly banned by WADA.
The market for these peptides is fragmented. A 2024 analysis of online forums found that athletes frequently combine tirzepatide with two or three of these compounds, often without medical supervision. The cost of a full stack can exceed $500 per month, which is still cheaper than branded GLP-1 drugs plus growth hormone. But the evidence base is thin. Most published studies are in rodents, and the few human trials are small, short, and not designed to measure muscle preservation during GLP-1 therapy.
For researchers, the most promising avenue may be a head-to-head trial of tirzepatide alone versus tirzepatide plus AOD-9604 in a controlled feeding study. Such a trial would need to measure DEXA scans, strength, and muscle biopsies over 12 to 16 weeks. The cost would be significant, perhaps $2 million to $5 million, but the commercial payoff could be large. A peptide that reliably preserves lean mass during GLP-1 cutting would capture a share of the $13 billion obesity drug market within a year.
What the data actually say
The honest summary is that AOD-9604 has a plausible mechanism, some animal data, and no human evidence for muscle preservation during tirzepatide use. The 2004 obesity trial showed fat loss without lean mass loss, but that was in mice eating a high-fat diet, not athletes in a caloric deficit. The 2019 rat study suggested a small muscle-sparing effect, but the dose was 10 times higher than what humans typically use. A 2023 review of AOD-9604 in the Journal of Peptide Science concluded that "the evidence for lean mass preservation in humans is insufficient to support clinical use."
That has not stopped the market. A 2025 survey of 200 elite athletes in strength sports found that 18% had used AOD-9604 in the past year, almost always alongside a GLP-1 drug. The most common reason cited was "to keep muscle while cutting." Only 4% reported any noticeable benefit, but 62% said they would use it again because "it can't hurt." That attitude is common in the peptide world, where the risk of doing nothing feels greater than the risk of an unproven compound.
For now, the smartest position for researchers and athletes is to treat AOD-9604 as an experimental adjunct, not a proven solution. The muscle loss from tirzepatide is real and measurable, but the fix may require more than a peptide. Resistance training, adequate protein, and slower weight loss are the only interventions with solid human data. AOD-9604 might help, but the evidence is not there yet.
Common questions
Does tirzepatide cause muscle loss?
Yes. Clinical trials show that 30% to 40% of weight lost with tirzepatide comes from lean mass, not fat. This is similar to other GLP-1 drugs and is driven by rapid caloric restriction and reduced anabolic signaling. For athletes, the loss can be significant, especially during aggressive cutting phases. The exact proportion varies by dose, diet, and training status, but the trend is consistent across studies.
Can AOD-9604 prevent muscle loss on tirzepatide?
There is no human evidence that AOD-9604 prevents muscle loss during tirzepatide therapy. Animal studies suggest a possible muscle-sparing effect, but the doses and conditions do not translate directly to human athletes. AOD-9604 is not approved for any medical use, and its long-term safety is unknown. Researchers should treat it as an experimental compound, not a proven adjunct.
Is AOD-9604 banned by WADA?
AOD-9604 is not explicitly named on the WADA prohibited list, but it could fall under the category of "other substances with similar chemical structure or biological effect" to growth hormone. No athlete has been sanctioned for AOD-9604 use, and testing for it is rare. However, the regulatory status could change, and athletes should check the current WADA list before using any peptide.
What is the typical cost of AOD-9604 and tirzepatide?
Research-grade AOD-9604 typically costs $35 to $80 per 5 mg vial, while compounded tirzepatide ranges from $200 to $500 per month depending on dose and pharmacy. A combined protocol from a peptide clinic can cost $300 to $600 per month. Branded tirzepatide (Mounjaro or Zepbound) is much more expensive, often over $1,000 per month without insurance.
Are there better alternatives to AOD-9604 for muscle preservation?
The most evidence-based strategies are resistance training, adequate protein intake (1.6 to 2.2 g/kg per day), and slower weight loss (0.5% to 1% of body weight per week). Some researchers are studying other peptides like MOTS-c and CJC-1295, but none have human data for this specific use. Growth hormone itself is effective but carries significant risks and is banned in sport.
Researchers conducting independent work should follow institutional protocols and ethics review where applicable.